Cargando…

Novel Lactobacillus reuteri HI120 Affects Lipid Metabolism in C57BL/6 Obese Mice

Intestinal probiotics are a primary focus area of current medical research. Probiotics such as bifidobacteria and lactobacilli can positively impact obesity and other metabolic diseases by directly or indirectly affecting lipid metabolism. However, the precise mechanisms of these effects remain uncl...

Descripción completa

Detalles Bibliográficos
Autores principales: Sun, Ye, Tang, Yanqing, Hou, Xufeng, Wang, Hesong, Huang, Liuying, Wen, Junjie, Niu, Hongxin, Zeng, Weisen, Bai, Yang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7592399/
https://www.ncbi.nlm.nih.gov/pubmed/33195535
http://dx.doi.org/10.3389/fvets.2020.560241
_version_ 1783601176434966528
author Sun, Ye
Tang, Yanqing
Hou, Xufeng
Wang, Hesong
Huang, Liuying
Wen, Junjie
Niu, Hongxin
Zeng, Weisen
Bai, Yang
author_facet Sun, Ye
Tang, Yanqing
Hou, Xufeng
Wang, Hesong
Huang, Liuying
Wen, Junjie
Niu, Hongxin
Zeng, Weisen
Bai, Yang
author_sort Sun, Ye
collection PubMed
description Intestinal probiotics are a primary focus area of current medical research. Probiotics such as bifidobacteria and lactobacilli can positively impact obesity and other metabolic diseases by directly or indirectly affecting lipid metabolism. However, the precise mechanisms of these effects remain unclear. In our previous work, the novel strain Lactobacillus reuteri HI120 was isolated and identified. HI120 expresses high levels of linoleic isomerase, resulting in the production of large amounts of conjugated linoleic acid (CLA) when mixed with linoleic acid (LA). As HI120 can efficiently transform LA into CLA, the effect of HI120 on the lipid metabolism in C57BL/6 obese mice was studied and the underlying molecular mechanism was explored in vitro. The results revealed no significant change in the diet, body weight, and serum triglyceride levels in mice. However, serum cholesterol levels were significantly decreased. The underlying mechanism may involve a CLA-mediated reduction in the gene expression levels of NPC1L1, SREBP-2, and HMG-CR, resulting in reduced cholesterol synthesis and absorption. Thus, HI120 can be developed as a potential probiotic formulation. After oral administration, LA from certain food sources can be converted into CLA in the human intestine to contribute to the prevention and treatment of obesity and hyperlipidemia.
format Online
Article
Text
id pubmed-7592399
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-75923992020-11-13 Novel Lactobacillus reuteri HI120 Affects Lipid Metabolism in C57BL/6 Obese Mice Sun, Ye Tang, Yanqing Hou, Xufeng Wang, Hesong Huang, Liuying Wen, Junjie Niu, Hongxin Zeng, Weisen Bai, Yang Front Vet Sci Veterinary Science Intestinal probiotics are a primary focus area of current medical research. Probiotics such as bifidobacteria and lactobacilli can positively impact obesity and other metabolic diseases by directly or indirectly affecting lipid metabolism. However, the precise mechanisms of these effects remain unclear. In our previous work, the novel strain Lactobacillus reuteri HI120 was isolated and identified. HI120 expresses high levels of linoleic isomerase, resulting in the production of large amounts of conjugated linoleic acid (CLA) when mixed with linoleic acid (LA). As HI120 can efficiently transform LA into CLA, the effect of HI120 on the lipid metabolism in C57BL/6 obese mice was studied and the underlying molecular mechanism was explored in vitro. The results revealed no significant change in the diet, body weight, and serum triglyceride levels in mice. However, serum cholesterol levels were significantly decreased. The underlying mechanism may involve a CLA-mediated reduction in the gene expression levels of NPC1L1, SREBP-2, and HMG-CR, resulting in reduced cholesterol synthesis and absorption. Thus, HI120 can be developed as a potential probiotic formulation. After oral administration, LA from certain food sources can be converted into CLA in the human intestine to contribute to the prevention and treatment of obesity and hyperlipidemia. Frontiers Media S.A. 2020-10-14 /pmc/articles/PMC7592399/ /pubmed/33195535 http://dx.doi.org/10.3389/fvets.2020.560241 Text en Copyright © 2020 Sun, Tang, Hou, Wang, Huang, Wen, Niu, Zeng and Bai. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Veterinary Science
Sun, Ye
Tang, Yanqing
Hou, Xufeng
Wang, Hesong
Huang, Liuying
Wen, Junjie
Niu, Hongxin
Zeng, Weisen
Bai, Yang
Novel Lactobacillus reuteri HI120 Affects Lipid Metabolism in C57BL/6 Obese Mice
title Novel Lactobacillus reuteri HI120 Affects Lipid Metabolism in C57BL/6 Obese Mice
title_full Novel Lactobacillus reuteri HI120 Affects Lipid Metabolism in C57BL/6 Obese Mice
title_fullStr Novel Lactobacillus reuteri HI120 Affects Lipid Metabolism in C57BL/6 Obese Mice
title_full_unstemmed Novel Lactobacillus reuteri HI120 Affects Lipid Metabolism in C57BL/6 Obese Mice
title_short Novel Lactobacillus reuteri HI120 Affects Lipid Metabolism in C57BL/6 Obese Mice
title_sort novel lactobacillus reuteri hi120 affects lipid metabolism in c57bl/6 obese mice
topic Veterinary Science
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7592399/
https://www.ncbi.nlm.nih.gov/pubmed/33195535
http://dx.doi.org/10.3389/fvets.2020.560241
work_keys_str_mv AT sunye novellactobacillusreuterihi120affectslipidmetabolisminc57bl6obesemice
AT tangyanqing novellactobacillusreuterihi120affectslipidmetabolisminc57bl6obesemice
AT houxufeng novellactobacillusreuterihi120affectslipidmetabolisminc57bl6obesemice
AT wanghesong novellactobacillusreuterihi120affectslipidmetabolisminc57bl6obesemice
AT huangliuying novellactobacillusreuterihi120affectslipidmetabolisminc57bl6obesemice
AT wenjunjie novellactobacillusreuterihi120affectslipidmetabolisminc57bl6obesemice
AT niuhongxin novellactobacillusreuterihi120affectslipidmetabolisminc57bl6obesemice
AT zengweisen novellactobacillusreuterihi120affectslipidmetabolisminc57bl6obesemice
AT baiyang novellactobacillusreuterihi120affectslipidmetabolisminc57bl6obesemice